Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy

Author:

Scimeca Manuel1ORCID,Rovella Valentina2ORCID,Palumbo Valeria1ORCID,Scioli Maria Paola1,Bonfiglio Rita1,Melino Gerry1,Piacentini Mauro3,Frati Luigi45,Agostini Massimiliano1ORCID,Candi Eleonora1,Mauriello Alessandro1ORCID,

Affiliation:

1. Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133 Rome, Italy

2. Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy

3. Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy

4. Institute Pasteur Italy-Cenci Bolognetti Foundation, Via Regina Elena 291, 00161 Rome, Italy

5. IRCCS Neuromed S.p.A., Via Atinense 18, 86077 Pozzilli, Italy

Abstract

Cholangiocarcinoma is a highly aggressive cancer arising from the bile ducts. The limited effectiveness of conventional therapies has prompted the search for new approaches to target this disease. Recent evidence suggests that distinct programmed cell death mechanisms, namely, apoptosis, ferroptosis, pyroptosis and necroptosis, play a critical role in the development and progression of cholangiocarcinoma. This review aims to summarize the current knowledge on the role of programmed cell death in cholangiocarcinoma and its potential implications for the development of novel therapies. Several studies have shown that the dysregulation of apoptotic signaling pathways contributes to cholangiocarcinoma tumorigenesis and resistance to treatment. Similarly, ferroptosis, pyroptosis and necroptosis, which are pro-inflammatory forms of cell death, have been implicated in promoting immune cell recruitment and activation, thus enhancing the antitumor immune response. Moreover, recent studies have suggested that targeting cell death pathways could sensitize cholangiocarcinoma cells to chemotherapy and immunotherapy. In conclusion, programmed cell death represents a relevant molecular mechanism of pathogenesis in cholangiocarcinoma, and further research is needed to fully elucidate the underlying details and possibly identify therapeutic strategies.

Funder

Min Salute-PNRR

PNCHLS-DA project INNOVA Diagnostica Avanzata

Associazione Italiana per la Ricerca contro il Cancro

EC

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3